Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening

PLoS One. 2013;8(4):e59315. doi: 10.1371/journal.pone.0059315. Epub 2013 Apr 2.

Abstract

Heat shock protein 90 (Hsp90), whose inhibitors have shown promising activity in clinical trials, is an attractive anticancer target. In this work, we first explored the significant pharmacophore features needed for Hsp90 inhibitors by generating a 3D-QSAR pharmacophore model. It was then used to virtually screen the SPECS databases, identifying 17 hits. Compound S1 and S13 exhibited the most potent inhibitory activity against Hsp90, with IC50 value 1.61±0.28 μM and 2.83±0.67 μM, respectively. Binding patterns analysis of the two compounds with Hsp90 revealed reasonable interaction modes. Further evaluation showed that the compounds exhibited good anti-proliferative effects against a series of cancer cell lines with high expression level of Hsp90. Meanwhile, S13 induced cell apoptosis in a dose-dependent manner in different cell lines. Based on the consideration of binding affinities, physicochemical properties and toxicities, 24 derivatives of S13 were designed, leading to the more promising compound S40, which deserves further optimization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Binding Sites
  • Cell Line, Tumor
  • Computer Simulation*
  • Databases, Factual
  • Drug Design*
  • Drug Evaluation, Preclinical* / methods
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Inhibitory Concentration 50
  • Ligands*
  • Models, Molecular
  • Molecular Conformation
  • Protein Binding
  • Quantitative Structure-Activity Relationship*

Substances

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Ligands

Grants and funding

This work is supported by the project 81230078 (key program), 81202463 (youth foundation) and 91129732 of National Natural Science Foundation of China, 863 of the State Key Program, Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (JKGQ201103), 2008ZX09401-001 and 2009ZX09501-003 of National Major Science and Technology Project of China (Innovation and Development of New Drugs). The authors declare no other conflicts of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.